Metformina + Sitagliptina Generis (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, reducing the amount of glucose produced by the liver, and by enhancing peripheral insulin sensitivity, which helps muscle and fat cells take up glucose more efficiently.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for this combination in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

Enquiries can be submitted through the product page on gnhindia.com by entering the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The metformin‑sitagliptin combination offers dual mechanisms—reduced hepatic glucose output and enhanced incretin activity—providing effective glycemic control with a lower risk of hypoglycemia compared with sulfonylureas, while avoiding the injectable route required for insulin or GLP‑1 analogues.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight and excessive heat to maintain stability and potency throughout the shelf life.

The medication is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events include lactic acidosis (primarily linked to metformin), acute pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, hepatic failure, and severe hypoglycemia when combined with other glucose‑lowering agents. Prompt medical attention is required if any of these occur.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, active liver disease, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with a documented allergy to any component of the product.